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The C-peptide of proinsulin is important for the biosynthesis of insulin and has for a long time been considered to be biologically
inert. Animal studies have shown that some of the renal eﬀects of the C-peptide may in part be explained by its ability to stimulate
the Na,K-ATPase activity. Precisely, the C-peptide reduces diabetes-induced glomerular hyperﬁltration both in animals and
humans, therefore, resulting in regression of ﬁbrosis. The tubular function is also concerned as diabetic animals supplemented
with C-peptide exhibit better renal function resulting in reduced urinary sodium waste and protein excretion together with the
reduction of the diabetes-induced glomerular hyperﬁltration. The tubular eﬀectors of C-peptide were considered to be tubule
transporters, but recent studies have shown that biochemical pathways involving cellular kinases and inﬂammatory pathways may
also be important. The matter theory concerning the C-peptide eﬀects is a metabolic one involving the eﬀects of the C-peptide on
lipidic metabolic status.This review concentrates on the most convincing data which indicate that the C-peptide is a biologically
active hormone for renal physiology.
Copyright © 2008 L. Rebsomen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Diabetes mellitus is a chronic metabolic disorder relative
to insulin deﬁcit that induces metabolic and degenerative
complications in various organs, including nerves, heart,
and kidneys [1]. C-peptide, secreted in blood stream in
equimolar amounts with insulin, was considered to be a reli-
able marker of residual beta-cell function [2–4]. During the
past decade, numerous studies in both humans and animals
have demonstrated that C-peptide, although not inﬂuencing
blood sugar control, might play a role in preventing and
potentially reversing some of the chronic complications of
type1diabetes,especiallydiabeticnephropathy[5–23].Thus
C-peptide may be an active peptide with relevant physiologic
eﬀects diﬀerent from and complementary to those of insulin
[24]. Several theories have been raised to explain C-peptide
eﬀects on renal function during diabetes. This review focuses
on the most convincing theories that are implicated in C-
peptide eﬀects on renal function.
2. C-PEPTIDE AND GLOMERULAR FUNCTION
2.1. C-peptideEffectsonRenalFunctionhavebeen
DemonstratedinHumans
Johansson et al. conducted a double blind study that
measured glomerular ﬁltration rate and proteinuria in type
1 diabetic patients with basal microalbuminuria, a marker
of early stages of diabetic nephropathy. After three months
of substitution by both C-peptide and insulin, patients
exhibited a better glycemic control, a reduction of diabetes-
induced glomerular hyperﬁltration and microalbuminuria
[7]. In another study, they conﬁrmed that proteinuria
was signiﬁcantly reduced in the C-peptide group during
the cross-over period [9]. Both studies were conducted
in diabetic patients so that the eﬀects of C-peptide could
not be diﬀerentiated from an improved glycemic control.
However, the same group examined the short-term eﬀect
of C-peptide infusion on renal function in insulin-treated
diabetic patients and found similar results on glomerular
ﬁltration rate [5]. Altogether, these papers strongly argue for
a speciﬁc C-peptide-related eﬀect on glomerular function.
Recently, Fiorina et al. observed that renal and pancreatic
transplantation of diabetic patients resulted in a better renal
graft outcome.
They observed kidney and erythrocyte Na,K-ATPase
activity, and stabilization of microalbuminuria correlated
with residual pancreatic secretion [14, 15]. In chronic
renal failure type 1 diabetic patients, residual pancreatic
activity,restoredbykidney-pancreastransplantationresulted
in enhanced kidney graft survival, hypertrophy, and vascular
function [25]. Furthermore, combined kidney-pancreas2 Experimental Diabetes Research
transplantationwasassociatedwithbetterhigh-energyphos-
phates metabolism than in kidney alone transplantation,
suggesting that restoration of beta-cell function positively
aﬀectskidneygraftmetabolism [26].Allthesedata raisedthe
question of C-peptide being a “kidney protector” [27].
2.2. SimilarStudieswereConductedinAnimalModels
In experimental conditions, several groups have shown that
streptozotocin-induced diabetic rats treated with C-peptide
exhibit improvement ofmetabolic status,renalfunction,and
reversal of some of the morphologic changes associated with
diabetic nephropathy [20, 21, 28].
Sjoquist et al. showed that perfusion of C-peptide results
in signiﬁcantly reduction of both proteinuria and diabetes-
induced glomerular hyperﬁltration which is considered to
be the initial state of diabetic nephropathy in streptozotocin
rats. They also showed that C-peptide also restores renal
functional reserve [20]. In another study, they conﬁrmed
that 14 days of C-peptide perfusion prevented glomerular
hypertrophy [21].
Theses results were conﬁrmed by Kamikawa et al. that
could demonstrate, in the same experimental model, that C-
peptide suppresses diabetes-induced abnormal glomerular
eNOS expression [29].
The mechanisms involved in glomerular eﬀects was
supposed to be an constriction of the glomerular aﬀerent
arteriols [30].
Altogether, these studies suggest that the absence of C-
peptide contributes to the initial state of diabetic nephropa-
thy.EvidencecomesfromspeciﬁcstudiesthattheC-terminal
EVARQ fragment of the C-peptide molecule is responsible
for most of the observed eﬀects [31].
Although seducing, the glomerulocentric view of renal
function during diabetes has been challenged by Thomson
et al. that explored to tubuloglomerular feedback in this
situation [32]. The results of their studies clearly established
that a tubulocentric view of diabetes-associated nephropathy
could be considered [33].
Interestingly, renal C-peptide eﬀects were also constant
with this hypothesis.
3. C-PEPTIDE AND TUBULAR FUNCTION
More than twenty years ago, Wald et al. suggested that
tubular Na,K-ATPase activity was related to glomerular
ﬁltration rate during diabetes [34]. Several groups have
conﬁrmed the time-dependant evolution of Na,K-ATPase
activity during diabetes, and the role of Na transport (for
review see [35]). Recently, Kim et al. have raised the
hypothesis that uncontrolled diabetes results in increased
levels of several proteins including sodium transporters such
as BSC1. They suggested that the enhanced expression of
sodium transporters are compensatory changes that prevent
a progressive decline in urinary concentrating ability despite
the continuing osmotic diuresis [36]. Thus they showed that
the regulation of BSC1 was not dependant on vasopressin
during streptozotocin-induced diabetes in brattelboro rats
[36]. Bardoux et al. have shown that vasopressin plays a
crucial role in the onset and aggravation of the renal com-
plications of diabetes. The mechanisms involve the tubular
ﬂuidintheloopofHenle,inhibitionofthetubuloglomerular
feedback control of glomerular function, and alterations in
glomerular hemodynamics [37].
All these data support the hypothesis that the renal
tubuleisinvolvedearlyinthecourseofdiabeticnephropathy.
Therefore, the eﬀects of C-peptide substitution on renal
tubule during type 1 diabetes were considered.
3.1. TheTransportTheory
The Na,K-ATPase is an ubiquitous membrane-bound
enzyme complex that plays fundamental role in cellular
function. The basic function of the Na,K-ATPase is to
maintain the high Na+ and K+ gradient across the plasma
membrane of animal cells, at the expense of ATP hydrolysis
(for review see [38]). Cellular C-peptide action is mediated
through Na,K-ATPase activation in various organs including
kidney [18, 19, 39]. Interestingly, Na+,K+-ATPase activity is
increasedduringtheﬁrstweeksafterdiabetesonset,andthen
decreased in various organs damaged by long-term diabetic
degenerative complications, including kidney [40–47].
We have shown that C-peptide restores both glomerular
and tubular function in diabetic rats. In vivo, C-peptide
supplementation for one month improved body weight
in streptozotocin-induced diabetic rats and decreased uri-
nary sodium wasting [28]. A compensatory mechanism
to conserve water and solute may involve changes in the
abundance of the medullary transport proteins involved in
the sodium handling. In a recent study, we observed that
in vivo C-peptide supplementation for one month induced
no changes in kidney abundance and transcription status of
several tubular sodium transporters including the epithelial
sodium channel (EnaC), and NKCC2/BSC1 cotransporter
in diabetic rats. In this study, rats were made diabetic after
streptozotocin injection and then were submitted to infusion
with physiological doses of either insulin, homologous C-
peptide, or both (unpublished data). Thus the transport
theory of C-peptide’s action is probably not relying on
changes in amounts of renal tubule Na transporters.
3.2. TheBiochemicalTheory
Even if the trigger of sodium Na transport is not dependent
on changes in Na transporters, the eﬀects on Na,K-ATPase
activity and expression are permanent ﬁndings. Several
groups have shown that C-peptide action was probably
secondary to biochemical changes. The ﬁrst argument was
found in renal cells that exhibited intracellular calcium
increase secondary to C-peptide exposure [18]. Then several
groups showed that incubation of various cell line types
with C-peptide resulted in PKC, MAPK, ERK activation (for
review see [24]).
Other studies have suggested that diabetes is a state of
increased renal nitric oxide (NO) activity as assessed by
urinary excretion of nitrites and nitrates (NOx), and that
NO synthase inhibitors reverse the increased glomerular
ﬁltration rate (GFR) observed in experimental diabetes.L. Rebsomen et al. 3
Interestingly, in contrast to the eﬀects on renal haemody-
namics, NO does not play an important role in the altered
renal sodium handling observed in experimental diabetes
[48].
3.3. TheInﬂammatoryTheory
C-peptide causes multiple molecular and physiological
eﬀects, and improves renal and neuronal dysfunction in
patients with diabetes. However, whether C-peptide con-
trols the inhibitor kappaB (IkappaB)/NF-kappaB-dependent
transcription of genes, including inﬂammatory genes
was unknown. Peroxisome proliferator-activated receptor
gamma (PPARgamma) has key roles in the regulation of adi-
pogenesis, inﬂammation, and lipid and glucose metabolism.
These issues were progressively answered. In an in vitro
model, both insulin and C-peptide induced a concentration-
dependentstimulationofPPARgammatranscriptionalactiv-
ity [49]. Another step was made by Kitazawa et al. that
showed that C-peptide stimulates the transcription of
inﬂammatory genes via activation of a PKC/IkappaB/NF-
kappaB signaling pathway [50]. The inﬂammatory theory
was further supported by Maezawa et al. that reported C-
peptide TGF-beta surppession in STZ-model [51].
These experimental data conﬁrm that C-peptide exerts a
wide range of cellular eﬀects (see Figure 1). Some of them
may be relevant to explain renal tubular eﬀects.
3.4. Themetabolictheory
The eﬀects of C-peptide on lipidic metabolic status have
not been documented yet. Thus the eﬀects of C-peptide on
PPAR expression triggered the curiosity on the role of the
adipocytenetworkanditsrelationshipwithrenalphysiology.
PreliminaryresultsofourgroupshowedthatC-peptideinfu-
sion for one month improved lipidic status of streptozotocin
rats, by reducing cholesterol and triglycerid levels, but did
not inﬂuence renal PPAR gamma expression (rebsomen et
al. work in progress). On the other side, C-peptide reduced
the adiponectin released by human adipocytes (Khammar et
al. work in progress). Thus if the mechanism of C-peptide
eﬀect on lipid metabolism remains to be elucidated, it is
knownthatdiabetesresultsininhibitionofseveralenzymatic
reactions that are accessible to nutritional supplementation,
and inﬂuence renal tubular physiology [52]. Although the
metabolic theory stays to be documented, both the inﬂuence
of the PPAR system on diabetic nephropathy and of C-
peptide on PPAR are becoming obvious [53, 54].
In addition, these studies strongly suggest that both renal
glomerule and tubule are a major site of C-peptide action.
During type 1 diabetes, C-peptide substitution restores in
part the functional properties of the renal tubule and,
therefore, allows better renal function and metabolic status.
4. CONCLUSION
In humans, C-peptide exerts a regulatory and physiologic
inﬂuence on renal function in patients with type 1 diabetes.















Figure 1: Modelization of C-peptide eﬀects on renal tubule. The
EVARQ fragment of C-peptide binds to a membrane G-protein
couple receptor of a tubule cell. Intracellular calcium increase
results in activation of PKCa and aﬀects Na,K-ATPase activity.
Together with this eﬀect, an increase of intracellular kinases results
in either activation or inhibition of inﬂammatory mediators. Green
indicates stimulation, red inhibition. Arrows in dash lines are
suggested pathways.
improvements in kidney graft survival rates and function
among uremic patients with type 1 diabetes mellitus and
kidney grafts. This suggests that together with the positive
eﬀectsofnormalization ofglycometaboliccontrol,successful
islet transplantation exerts beneﬁcial eﬀects on kidney func-
tion, in part by restoring the C-peptide secretion, a situation
closer to the endogenous pancreatic function. Although
the mechanisms are not fully understood, a hormonal
therapeutic role of C-peptide as an active protective factor
for the diabetic kidney should be considered.
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